The Market Herald - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Respiri has announced an update regarding its wheezo technology
  • Pilot use of wheezo will lead to clinical credibility and will replicate the protocol from the first Australian based trial
  • wheezo helps monitor and manage asthma

After a visit from Indian joint venture partner MedAchievers, Respiri has announced an update regarding its wheezo asthma monitoring technology.

The pilot use of wheezo will lead to clinical credibility and will replicate the protocol from the first Australia-based trial.

The wheezo product is used to monitor and manage the symptoms of asthma. It provides asthma management diary features, medication usage and reminders, and symptoms and triggers to help asthma sufferers gain a better understanding of how their condition affects them.

Further features such as pollen count and weather conditions are currently being planned for integration into the device.

According to Respiri, the wheezo monitor has advanced ergonomics and the best in class components. The next generation is moving into the compliance testing phase of development to complete asthma management.

The visit from Dr Harsha Vardhan, the founder of MedAchievers, included a site visit to the manufacturing facility in the Dandenong suburb in Melbourne, planning for large demand requirements in India, and the process of delivering the product.

“With Respiri, MedAchievers firmly believes that we will provide an avenue to improved asthma and COPD [chronic obstructive pulmonary disease] care,” Dr Harsha said.

“Our studies and market entry activities using the Respiri technology and MedAchievers clinical strength are forming a very important partnership which will improve patient lives,” he said.

The continued planning for large scale orders and clinical studies are significant steps forward following the introduction into the Indian market via the Delhi MedAchievers-hosted MedParliament in July 2019.

Pre-market use of wheezo involves three large healthcare institutions with over 4500 beds combined in North and South India.

It will begin in the first week of October with 50 wheezo devices facilitating clinical acceptance and treatment protocols in the lead up to complete roll out of it to patients.

Besides Respiri’s joint venture in India, it is also aiming to obtain product certification for device sales in the Australian and European markets and to undertake clinical trials to provide confidence in the performance of the device and app.

RSH by the numbers
More From The Market Herald

The Calmer Co locks in $700k in funding via convertible note issue

The Calmer Co (ASX:CCO) has confirmed its receipt of $700,000 in funding from existing shareholders.

FDA greenlights Botanix Pharmaceuticals’ Sofdra resubmission plan

FDA approves Botanix's strategy for Sofdra NDA resubmission with no additional materials requested, keeping submission to…

Botanix Pharmaceuticals successfully closes $13.5m Placement to boost US commercial activities

Botanix Pharmaceuticals (ASX: BOT) has closed its $13.5 million placement to both new and existing institutional…

Pharmaust completes Phase One Monepantel study and files for Orphan Drug Designation

Pharmaust (ASX:PAA) has announced that all patients have completed its phase one MEND study using monepantel…